Please use this identifier to cite or link to this item:
https://hdl.handle.net/11499/30014
Title: | The effects of bosentan on hyperoxia-induced lung injury in neonatal rats | Authors: | Özdemir, Özmert M.A. Taban, Özgün Enli, Yaşar Bir, Ferda Şahin, Barbaros Ergin, Hacer |
Keywords: | bosentan hyperoxia-induced lung injury treatment interleukin 10 interleukin 1beta interleukin 6 smooth muscle actin tumor necrosis factor actin biological marker endothelin receptor antagonist smooth muscle actin, rat animal experiment animal tissue Article body weight comparative study controlled study drug effect histopathology lung fibrosis lung parenchyma newborn nonhuman pneumonia priority journal protein blood level rat respiratory tract disease assessment surface area animal biosynthesis complication disease model hyperoxia immunohistochemistry intraperitoneal drug administration lung lung injury metabolism pathology treatment outcome Wistar rat Actins Animals Animals, Newborn Biomarkers Bosentan Disease Models, Animal Endothelin Receptor Antagonists Hyperoxia Immunohistochemistry Injections, Intraperitoneal Lung Lung Injury Rats Rats, Wistar Treatment Outcome |
Publisher: | Blackwell Publishing | Abstract: | Background: Bronchopulmonary dysplasia (BPD) remains an important cause of morbidity and mortality in premature infants. There is currently no proven effective treatment modality for BPD, and inflammation and oxidative injury play an important role in the pathogenesis of this disease. This study investigated the histopathological and biochemical effects of bosentan, which is a non-specific endothelin receptor antagonist with known antioxidant and anti-inflammatory properties, on hyperoxia-induced lung injury (HILI) in neonatal rats. Methods: The experiment was performed on newborn rats from the 3rd to the 13th postnatal day. The rats were randomly divided into six groups: Group 1 (air-exposed + saline, n = 6); Group 2 (HILI, n = 8); Group 3 (air-exposed + bosentan, n = 7); Group 4 (HILI + saline, n = 7); Group 5 (HILI + early bosentan-treated group, n = 6), and Group 6 (HILI + late bosentan-treated group, n = 7). Bosentan was administered (30 mg/kg/day) intraperitoneally. The histopathological effects of bosentan on lung tissue were assessed by their alveolar surface area, fibrosis, and smooth muscle actin (SMA) scores, and the biochemical effects on lung tissue were assessed by interleukin-1 beta (IL-1ß), IL-6, IL-10, and tumor necrosis factor-alpha (TNF-?). Results: The alveolar surface area and fibrosis scores were found to be significantly higher in HILI groups compared with Group 1 (P < 0.01). The SMA scores in HILI groups were also significantly higher than Group 1 (P < 0.01). Bosentan treatment, especially late therapy, reduced all of these histopathological scores and the levels of IL-6 and TNF-? in the hyperoxia groups (P < 0.01). Conclusion: This experimental study showed that bosentan had a protective effect on hyperoxic lung injury through its anti-inflammatory properties. © 2019 Japan Pediatric Society | URI: | https://hdl.handle.net/11499/30014 https://doi.org/10.1111/ped.14013 |
ISSN: | 1328-8067 |
Appears in Collections: | PubMed İndeksli Yayınlar Koleksiyonu / PubMed Indexed Publications Collection Scopus İndeksli Yayınlar Koleksiyonu / Scopus Indexed Publications Collection Tıp Fakültesi Koleksiyonu WoS İndeksli Yayınlar Koleksiyonu / WoS Indexed Publications Collection |
Show full item record
CORE Recommender
SCOPUSTM
Citations
4
checked on May 5, 2024
WEB OF SCIENCETM
Citations
5
checked on Sep 30, 2024
Page view(s)
56
checked on Aug 24, 2024
Google ScholarTM
Check
Altmetric
Items in GCRIS Repository are protected by copyright, with all rights reserved, unless otherwise indicated.